

RESULTS PREVIEW

Technology Hardware & Equipment

13 January 2025

Scanfil

Finland



COMMISSIONED RESEARCH

Research analysts: Jakob Söderblom Johan Wettergren

Share price: EUR8.3 Fair value range: EUR8.8–10.6

Expecting the best quarter of 2024 – Q4 preview

SRX contribution supports sales development in Q4(24)

For Q4(24), we model Scanfil to report sales growth of -5%, a clear sequential improvement from the -19% reported in Q3(24). This is primarily driven by the contribution from the acquired SRX Global, as we continue to expect the European industrial markets to be characterised by uncertainty, thus we model -9% organic growth in Q4(24). While we believe that demand has stabilised in recent months, we still believe a clearer rebound won't show until later in 2025e. On margins, we expect Scanfil to continue illustrating the results of its continued focus on operational efficiency, and model for an adj. EBIT margin of 7.1% – bringing the full-year margin to 6.9%, just shy of the company's long-term target range of 7–8%. Remember that Scanfil in December revised guidance for 2024 downwards to sales of EUR770–780m (780–840m) and adj. EBIT of EUR53–54m (54–61m).

Small changes to underlying estimates ahead of the report release

Ahead of the report release for the fourth quarter of 2024, we make only minor changes to our estimate profile. As such, we lower our adjusted EBIT(2024-25e) by 3%, primarily stemming from lower growth assumptions.

Slight increase in our fair value range to EUR8.8-10.6 (8.7-10.6)

Following the small negative changes to our estimates, the change to our fair value range is instead primarily driven by the mechanical effect of approaching the end-date of our medium-term valuation approach. In our valuation of Scanfil, we apply a medium-term view, we apply a 9.0–11.0x EV/EBIT exit multiple to our 2026 estimates, discounted to the present. In an industry with a historical strong correlation, we believe investors should pay attention to Scanfil's top-tier capital efficiency, healthy cash generation, as well as the strong financial position allowing for additional value-creating M&A in the years to come.

Changes in this	report			Key figures (EUR)	2023	2024e	2025e	2026e	Share	price - 5Y	·		
	From	То	Chg	Sales (m)	902	777	844	895	I 2.0	1			
EPS adj. 2024e	0.65	0.63	-3%	EBITDA (m)	80	73	80	87	11.0			1	
EPS adj. 2025e	0.74	0.71	-3%	EBIT (m)	61	54	61	66	10.0			Λ	
EPS adj. 2026e	0.79	0.77	-3%	EPS	0.74	0.63	0.71	0.77	9.0				
•				EPS adj.	0.74	0.63	0.71	0.77		I			
				DPS	0.23	0.23	0.24	0.26	0.8	1 . /"	Mal	A WI	W
				Sales growth Y/Y	7%	-14%	9%	6%	7.0	۲.	. WA	1	'' '
Key facts				EPS adj. growth Y/Y	39%	-15%	13%	8%	6.0		M	M.	
No. shares (m)			65.2	EBIT margin	6.8%	6.9%	7.2%	7.4%	5.0	h el Y	_ [W]	mun	wh.
Market cap. (USD	m)		555	P/E adj.	11.2	13.1	11.6	10.8	4.0	N.			
Market cap. (EUR	'		541	EV/EBIT	9.1	10.3	9.1	8.4	3.0	r			
Net IB Debt. (EUI	'		14	EV/EBITA	9.1	10.3	9.1	8.4	J	an Jan)20 2021	Jan	Jan Jan	Jan
Adjustments (EUF	-		0	EV/EBITDA	7.0	7.6	6.9	6.3	20	2021	2022 2	2023 2024	2025
EV (2024e) (EURr	'		555	P/BV	2.0	1.9	1.7	1.5		S	canfil		
Free float	,		36.0%	Dividend yield	2.8%	2.8%	2.9%	3.1%					
Avg. daily vol. ('00)())		15	FCF yield	8.7%	14.6%	4.9%	6.5%		C	MX Helsi	nki_PI (Rebase	ed)
Risk)	Mediu	m Risk	Equity/Total Assets	51.4%	55.7%	56.6%	57.6%	High/Lc	w (12M)			EUR8.6/7
Fiscal year end			ember	ROCE	18.2%	15.0%	15.5%	15.3%	Perf.	3M	6M	12M	YTD
Share price as of ((CFT)	13 Jan 202		ROE adj.	19.6%	14.8%	15.1%	I 4.8%	Abs.	13.5	6.4	12.2	0.6
Share price as or ((021)	10 juii 202.		Net IB debt/EBITDA	0.6	0.2	0.1	0.1	Rel.	<u>19.4</u>	11.0	18.6	-0.3

Source: Carnegie Research, FactSet, Millistream & company data

This report has been commissioned and sponsored by Scanfil. Commissioned research is considered to be marketing communication (i.e. not investment research under MiFID II). This material may be subject to restrictions on distribution in certain areas. For more information, see disclosures and disclaimers at the end of this report

Upcoming events

- Q4 Report: 21 Feb 2025
- QI Report: 24 Apr 2025
- AGM 2025: 25 Apr 2025
- Q2 Report: 17 Jul 2025



Investment cas	se
Near term: 6–12m	Although we like Scanfil's organic and inorganic growth prospects, we are still somewhat cautious about a pick-up in industrial and cleantech demand in the next quarters. At the same time, we consider the company's blue-chip industrial customer portfolio to be sound, and we believe its strong financial position enables further M&A, which should add another vertical to Scanfil's investment case.
Long term: 5Y+	Long term, we expect continued specialisation among product companies as well as an increasing focus on regionalisation of supply chains to drive volumes towards more Europe- and North American-focused contract manufacturing companies. Considering Scanfil's position as one of the largest in terms of sales in Europe, we believe the company is well positioned to continue to win market shares. While we do not pencil in any significant margin improvement from current levels, we believe that re-rating possibilities exist if the company is able to showcase a margin in the upper end of its target of 7–8% adj. EBIT margins.
3 Key risks to investment	Prolonged and uncertainty and backdrop on European industrial markets.
case:	Intense competition having an adverse impact in pricing discussions with OEMs. Quality and delivery issues, whether stemming from internal or external factors, could have adverse effects on Scanfil's brand and reputation as a reliable supplier.

Company description

With origins dating back to 1976, Scanfil is one of the largest listed contract manufacturers in Northern Europe. Combining both mechanics assembly and industrial electronics, Scanfil aims to be the preferred manufacturing partners for demanding industrial customers in the low/mid-volume, high-mix niche of manufacturing. The company has a global factory footprint, operating facilities across Europe, the US, and APAC. Its customer portfolio primarily includes clients in the Industrial, Energy & Cleantech, and Medtech & Life Sciences niches.

Key industry drivers

- Continued focus on specialisation among OEMs
- Relocation strategies such as nearshoring/reshoring

Industry outlook

While we expect the sector to continue facing headwinds in H1(25), we expect to see sequential improvement across the year, primarily stemming from an improved industrial sentiment in Europe.

Largest shareholders

Harri Takanen	15.2%
Jarkko Takanen	12.6%
Varikot Oy	11.7%

Cyclicality Cyclicality: Yes

Mid

Key peers

Primary peers are in our view HANZA, Inission, and AQ Group. Other peers include electronics-focused contract manufacturers such as Note, Kitron, and Incap.

Valuation and methodology


Our fair value range is based on a medium-term approach on our 2026 estimates and an EV/EBIT(NTM) multiple of 9-11x, discounted to the present using a cost of capital of ~8%. We also compare our valuation of Scanfil to its historical valuation levels, as well as the current trading levels of its sector peers.

Upside/downside spectrum 12m




Bull case: A sharper-than-expected recovery in European industrial demand over the next quarters, together with additional M&A activities, helps drive earnings growth above our expectations. We also believe this could warrant a re-rating of Scanfil's multiple.

Bear case: Prolonged muted demand holding back volumes and subsequently also utilisation rates across Scanfil's factory footprint.




Scanfil in key charts



We expect an organic sales decline of 14% in 2024, before recovering in 2025–26e

Source: Carnegie Research, Company data




We expect sales growth to return to more normalised levels in 2025–26e, while an uptick in M&A could present upside potential to our explicit estimates

Energy & Cleantech sales grew at a

CAGR of 33% in 2020-23, but has

faced a tougher sentiment in 2024e

Source: Carnegie Research, Company data



Scanfil: Net sales development by customer segment


We expect Scanfil to reach its long-

term adj. EBIT margin of 7-8% in


2025-26e...







Source: Carnegie Research, Company data




Carnegie estimates vs. company guidance and targets

... but do not expect the company to reach its margin target for 2024e

Source: Carnegie Research, Company data





Source: Carnegie Research, Company data

Top-tier cash conversion has built one of the strongest balance sheets in the sector

			eviati	on ta	Die ar	iead o	of the	Q4	repoi	τ						
Scanfil	2023				2024				CA	Re						
EURm	QI	Q2	Q3	Q4	QI	Q2	Q3	Q4a	Q4e	Dev.	2022	2023	2024e	2025e	2026e	2027e
Net sales	224.6	243.3	212.8	220.8	198.9	195.5	173.3		208.9		843.7	901.6	776.6	844.2	894.8	939.6
Other operating income	0.1	0.2	0.4	0.2	0.1	0.3	0.3		0.2		0.9	0.9	0.9	1.1	0.9	0.9
Change of inventories in	1.5	-0.1	2.1	-3.9	0.2	-1.2	-0.1		0							
production, finished goods, and	1.5	-0.1	2.1	-3.7	0.2	-1.2	-0.1		0		0.3	-0.3	-1.1	0.0	0.4	0.5
Manufacturing for own use	0	0	0	0	0	0	0		0		0.0	0.0	0.0	0.0	0.0	0.0
Expenses	-206.5	-221.2	-195.3	-198.7	-181.5	-175.6	-156.2		-190.1		-782.0	-821.7	-703.4	-765.2	-808.9	-849.4
Depreciation and amortisation	-4.7	-4.7	-4.8	-4.9	-5	-5.1	-5.1		-4.2		-17.5	-19.1	-19.4	-19.4	-21.5	-22.5
Adj. EBIT	15.0	17.5	15.2	13.4	12.7	13.9	12.4		14.8		45.4	61.3	53.8	60.6	65.8	69.I
Adj. EBIT margin	6.7%	7.2%	7.1%	6. 1%	6.4%	7.1%	7.2%		7.1%		5.4%	6.8%	6.9 %	7.2%	7.4%	7.4%
EO	0	0	0	0	0	0	-0.3		0		0.0	0.0	-0.3	0.0	0.0	0.0
EBIT	15	17.5	15.2	13.4	12.7	13.9	12.1		14.8		45.4	61.3	53.5	60.6	65.8	69.I
Net financials	-0.6	0.9	-0.7	0.6	0.2	0.1	-0.2		-0.2		-3.7	0.3	-0.1	-1.0	-1.3	-1.3
РТР	14.5	18.4	14.6	14.1	12.9	14.0	11.9		14.6		41.7	61.6	53.4	59.6	64.5	67.8
Tax	-2.8	-3.9	-3.5	-3.2	-3.1	-3.1	-3.1		-3.2		-6.7	-13.4	-12.5	-13.1	-14.2	-14.9
Tax rate	-19%	-21%	-24%	-23%	-24%	-22%	-26%		-22%		-16%	-22%	-23%	-22%	-22%	-22%
Net profit	11.8	14.5	11	10.9	9.8	10.8	8.7		11.4		35.0	48.2	40.9	46.5	50.3	52.9
Reported EPS	0.18	0.22	0.17	0.17	0.15	0.17	0.13		0.18		0.53	0.74	0.63	0.71	0.77	0.81
Adj. EPS	0.18	0.22	0.17	0.17	0.15	0.17	0.14		0.18		0.53	0.74	0.63	0.71	0.77	0.81
Earnings																
EBITDA	19.7	22.2	20.0	18.3	17.7	19.0	17.2		19.0		62.8	80.4	72.9	80.I	87.2	91.6
EBIT	15.0	17.5	15.2	13.4	12.7	13.9	12.1		14.8		45.4	61.3	53.5	60.6	65.8	69.I
РТР	14.5	18.4	14.6	14.1	12.9	14.0	11.9		14.6		41.7	61.6	53.4	59.6	64.5	67.8
Net profit	11.8	14.5	11.0	10.9	9.8	10.8	8.7		11.4		35.0	48.2	40.9	46.5	50.3	52.9
Growth																
Sales growth Y/Y	14.2%	14.3%	0.4%	-0.7%	-11.4%	-19.6%	-18.6%		-5.4%		21.3%	6.9%	-13.9%	8.7%	6.0%	5.0%
- o/w organic	14.9%	16.9%	4.7%	1.7%	-10.2%	-19.4%	-18.8%		-8.7%		18.7%	9.4%	-14.4%	4.3%	6.0%	5.0%
- o/w structural	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%		4.2%		0.0%	0.0%	1.0%	3.6%	0.0%	0.0%
- o/w currency	-0.6%	-2.7%	-4.3%	-2.4%	-1.2%	-0.3%	0.2%		-0.5%		2.5%	-2.5%	-0.5%	0.8%	0.0%	0.0%
EBIT growth	45.6%	73.3%	32.2%	0.0%	-15.3%	-20.6%	-20.4%		10.7%		14.6%	35.1%	-12.7%	13.3%	8.5%	5.0%
Margins																
EBITDA margin	8.8%	9.1%	9.4%	8.3%	8.9%	9.7%	9.9%		9.1%		7.4%	8.9%	9.4%	9.5%	9.8%	9.8%
EBIT margin	6.7%	7.2%	7.1%	6.1%	6.4%	7.1%	7.0%		7.1%		5.4%	6.8%	6.9%	7.2%	7.4%	7.4%
PTP margin	6.5%	7.6%	6.9%	6.4%	6.5%	7.2%	6.9%		7.0%		4.9%	6.8%	6.9%	7.1%	7.2%	7.2%

Deviation table ahead of the Q4 report



Forecast changes ahead of the Q4(24) report

Ahead of the report release for the fourth quarter of 2024, we make marginal changes to our estimate profile. On 11 December, the company announced that it experienced some material shortage challenges related to a few customer deliveries, which we primarily refer to larger customers within the Industrial customer segment. In addition, the company also talked of a slight softening of demand. On the back of this, we lower our adj. EBIT(2024–25e) by 3%.

In conjunction with the announcement, Scanfil also revised its outlook for 2024. The company now estimates sales of EUR770–780m (780–840m), together with adj. EBIT of EUR53–54m (54–61m). Incorporating the newly acquired SRX Global into our estimates, we now forecast Scanfil to report sales of EUR209m in Q4, corresponding to a sales decline of 5%. We expect to see some adverse impact on the margin from the material shortages, hampering productivity, and model an adj. EBIT margin of 7.1% for the quarter. All in all, this brings our full-year sales estimate to EUR777m, joined by an adj. EBIT margin of 6.9%.

Scanfil		2024e			2025e		2026e			
EURm	Old	New 9	% change	Old	New 9	% change	Old	New %	6 change	
Net sales	785.1	776.6	-1%	865.7	844.2	-2%	917.6	894.8	-2%	
Other operating income	1.0	0.9	-1%	0.9	1.1	30%	0.9	0.9	-2%	
Change of inventories in production,			00/			1000			201	
finished goods, and work in progress	-1.1	-1.1	0%	0.4	0.0	-100%	0.5	0.4	-2%	
Manufacturing for own use	0.0	0.0	0%	0.0	0.0	0%	0.0	0.0	0%	
Expenses	-712.4	-703.4	-1%	-785.2	-765.2	-3%	-831.3	-808.9	-3%	
Depreciation and amortisation	-17.3	-19.4	12%	-19.0	-19.4	2%	-20.2	-21.5	6%	
EBIT adj.	55.2	53.8	-3%	62.7	60.6	-3%	67.4	65.8	-2%	
EO	0.0	-0.3	0%	0.0	0.0	0%	0.0	0.0	0%	
EBIT	55.2	53.5	-3%	62.7	60.6	-3%	67.4	65.8	-2%	
Net financials	-0.1	-0.1	0%	-1.0	-1.0	0%	-1.3	-1.3	0%	
РТР	55.1	53.4	-3%	61.7	59.6	-3%	66.1	64.5	-3%	
Tax	-12.9	-12.5	-3%	-13.6	-13.1	-3%	-14.6	-14.2	-3%	
Net profit	42.3	40.9	-3%	48.2	46.5	-4%	51.6	50.3	-3%	
							Sour	ce: Carnegie	Research	
Growth	Old	New 9	% change	Old	New 9	6 change	Old	New %	change	
Sales growth Y/Y	-13%	-14%	-90bps	10%	9%	-160bps	6%	6%	0bps	
- o/w organic	-13%	-14%	-90bps	7%	4%	-220bps	6%	6%	0bps	
- o/w structural	1%	1%	0bps	4%	4%	0bps	0%	0%	0bps	
- o/w currency	0%	0%	0bps	0%	1%	80bps	0%	0%	0bps	
EBIT growth	-10%	-13%	-280bps	13%	13%	-20bps	8%	8%	80bps	
Net profit growth	-12%	-15%	-280bps	14%	14%	-10bps	7%	8%	80bps	
Adj. EPS growth	-13%	-15%	-220bps	14%	13%	-90bps	7%	8%	80bps	
Margins										
Margins EBITDA margin	9.2%	9.4%	20bps	9.4%	9.5%	0bps	9.6%	9.8%	20bps	
	9.2% 7.0%	9.4% 6.9%	20bps - 10bps	9.4% 7.2%	9.5% 7.2%	0bps - 10bps	9.6% 7.4%	9.8% 7.4%	20bps 0bps	

Source: Carnegie Research




Fair value range raised to EUR8.8-10.6 (8.7-10.6) per share

In our valuation of Scanfil, we apply a medium-term approach due to the cyclical nature of some of the company's end-markets, and to look beyond the still-lingering market uncertainty and subsequent demand weakness we expect going into 2025e. Our financial expectations for 2026e form the basis of our valuation methodology and we apply a 9.0–11.0x EV/EBIT exit multiple range; the company's historical average is 10.3x. On our updated estimates, we raise our fair value range marginally to EUR8.8–10.6 (8.7–10.6). The positive impact to our fair value range stems from the mechanical effect of moving closer to the exit date of our valuation approach. Note that any potential contribution from future M&A is excluded from our estimates, and that this would present upside to our sales and earnings forecasts.

Scanfil has historically traded at a slight discount to its Nordic and European peers, which we think is reasonable considering its lower-margin profile and historically above-average customer concentration. While we find that the customer concentration risk in Scanfil has diminished significantly in recent years, we believe the discount is likely to remain until Scanfil is able to show EBIT margins in the upper end of its 7–8% target range, or a sustainable uptick in growth. On this note, we view the adj. EBIT result of 7.2% in Q3(24) as supportive, as well as the acquisition of SRX Global.

For 2026e, we model sales of EUR895m, sales growth of 6.0% and an adj. EBIT margin of 7.4%. Depending on order momentum and earnings trends, we believe there are likely re-rating scenarios for the Scanfil share. Moreover, we believe the capital markets currently underappreciate the M&A potential enabled by the company's strong balance sheet, solid capital turnover and attractive cash conversion capabilities. Thus, we value Scanfil using a set of different exit multiples of 9.0–11.0x, yielding a fair value range of EUR8.8–10.6 per share (8.7–10.6). Our fair value range corresponds to an EV/EBIT(25e) of 9.6–11.5x and P/E(25e) of 12.3–14.8x.





Source: Carnegie Research

To illustrate the potential impact on Scanfil's share price of an improved margin profile for the group, we have in the two tables below illustrated the valuation's inherent sensitivity to changes in EBIT margin assumptions and the exit multiple chosen by the company. Were Scanfil to reach the upper levels of its long-term target of an adj. EBIT margin of 7–8%, we believe a higher fair value range would be warranted both from the perspective of higher earnings and a higher multiple.

Sensitivity table (i) - Valuation per share on EBIT(26e) margin vs. exit multiple



	EBIT margi	n 2026e				EBIT margin 2026e											
	9.7	6.5%	6.8%	7.1%	7.4%	7.7%	8.0%	8.3%		9.7	6.5%	6.8%	7.1%	7.4%	7.7%	8.0%	8.3%
	7.0x	6.1	6.3	6.6	6.9	7.1	7.4	7.7		6.8%	8.7	9.1	9.5	9.8	10.3	10.7	11.1
ltiple	8.0x	6.9	7.2	7.5	7.8	8.1	8.4	8.7	e	7.3%	8.7	9.1	9.5	9.8	10.2	10.6	11.0
ulti	9.0x	7.7	8.1	8.4	8.8	9.1	9.4	9.8	rat	7.8%	8.6	9.0	9.4	9.7	10.2	10.6	11.0
Ē	10.0x	8.5	8.9	9.3	9.7	10.1	10.5	10.8	nut	8.3%	8.6	9.0	9.4	9.7	10.1	10.5	10.9
EBIT	11.0x	9.4	9.8	10.2	10.6	11.1	11.5	11.9	sco	8.8%	8.6	8.9	9.3	9.6	10.1	10.5	10.9
EVIE	12.0x	10.2	10.6	11.1	11.6	12.0	12.5	12.9	ā	9.3%	8.5	8.9	9.3	9.6	10.0	10.4	10.8
	13.0x	11.0	11.5	12.0	12.5	13.0	13.5	14.0		9.8 %	8.5	8.9	9.2	9.6	10.0	10.4	10.8

Source: Carnegie Research

Discount rate

Source: Carnegie Research

We have also included a sensitivity table illustrating the impact of different discount rates and exit multiples.

Sensitivity table (ii) - Valuation per share on EBIT(26e) margin vs. discount rate

Sensitivity table (iii) - Valuation per share on discount rate vs. exit multiple

	Discount ra	lle						
	9.7	6.8%	7.3%	7.8%	8.3%	8.8%	9.3%	9.8 %
	7.0x	7.0	6.9	6.9	6.9	6.8	6.8	6.8
iple	8.0x	7.9	7.9	7.8	7.8	7.8	7.7	7.7
multiple	9.0x	8.9	8.8	8.8	8.8	8.7	8.7	8.6
	10.0x	9.8	9.8	9.7	9.7	9.6	9.6	9.6
EV/EBIT	11.0x	10.8	10.7	10.7	10.6	10.6	10.5	10.5
I/I	l 2.0x	11.7	11.7	11.6	11.6	11.5	11.5	11.4
	13.0x	12.7	12.6	12.6	12.5	12.5	12.4	12.3

Source: Carnegie Research

Risks

Below we have highlighted some potential risks we see in Scanfil's investment case.

Intense competition

Scanfil may boast decade-long relationships with some of its customers, but competition in the contract manufacturing industry is still intense. If Scanfil were to become unable to meet its customers' demands in factors such as quality, reliability, and pricing, this could impact demand for its services.

Quality issues

As highlighted above, we believe quality is one of the key factors considered by Scanfil's customers. The company measures quality as defective parts per million, and states that the metric improved significantly in 2023. If concerns were to arise regarding the quality of the services offered by Scanfil, this could not only damage the company's financial development, but also its brand as a trusted manufacturing partner.

Customer concentration

In all businesses, there is an inherent risk that one or more customers outgrow other accounts to the extent that the customer portfolio becomes imbalanced. Thus, there is a risk that if one or more of Scanfil's larger customers were to reduce their order levels, it could have an adverse effect on the group's sales and earnings. In 2023, Scanfil's largest customer accounted for 13% of group sales, and the top ten cumulatively comprised 55% of sales. While we note that diversification has increased since the beginning of the 2010s, there is still a risk that a downturn in the largest customers' end-markets could have an adverse effect on Scanfil's bottom line.

Inherent industrial cyclicality

In our view, while Scanfil enjoys favourable exposure to structurally growing markets such as industrial electrification and medical technology, contract manufacturing remains a cyclical business niche to some extent. As such, weakening industrial demand and demand for investment goods might have a negative impact on Scanfil's operations. This could in turn lead to overcapacity among the company's production sites, weighing on utilisation rates and ultimately on earnings.



Interim figures Scanfil

P&L (EURm)	QI(24)	Q2(24)	Q3(24) Q	Q4(24e) Q	QI(25e) (Q2(25e) Q	Q3(25e) Q	Q4(25e)	2021	2022	2023	2024e	2025e	2026e	2027e
Net sales	198.9	195.5	173.3	208.9	206.3	212.7	199.2	226.0	695.7	843.7	901.6	776.6	844.2	894.8	939.6
Other operating income	0.1	0.3	0.3	0.2	0.3	0.3	0.3	0.3	1.2	0.9	0.9	0.9	1.1	0.9	0.9
Change of inventories in production, finished goods, and work in progress	0.2	-1.2	-0.1	0.0	0.0	0.0	0.0	0.0	3.0	0.3	-0.3	-1.1	0.0	0.4	0.5
Manufacturing for own use	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Expenses	-181.5	-175.6	-156.2	-190.1	-187.1	-192.9	-180.5	-204.8	-644.9	-782.0	-821.7	-703.4	-765.2	-808.9	-849.4
Depreciation and amortisation	-5.0	-5.1	-5.1	-4.2	-4.7	-4.9	-4.6	-5.2	-15.4	-17.5	-19.1	-19.4	-19.4	-21.5	-22.5
Adj. EBIT	12.7	13.9	12.4	14.8	14.7	15.2	14.4	16.3	42.0	45.3	61.3	53.9	60.6	65.8	69.I
EO	0.0	0.0	-0.3	0.0	0.0	0.0	0.0	0.0	-2.4	0.0	0.0	-0.3	0.0	0.0	0.0
EBIT	12.7	13.9	12.1	14.8	14.7	15.2	14.4	16.3	39.6	45.3	61.3	53.6	60.6	65.8	69.I
Net financials	0.2	0.1	-0.2	-0.2	-0.3	-0.3	-0.3	-0.3	-1.9	-3.7	0.3	-0.1	-1.0	-1.3	-1.3
РТР	12.9	14.0	11.9	14.6	14.4	14.9	14.2	16.1	37.7	41.7	61.6	53.5	59.6	64.5	67.8
Tax	-3.1	-3.1	-3.1	-3.2	-3.2	-3.3	-3.1	-3.5	-7.9	-6.7	-13.4	-12.5	-13.1	-14.2	-14.9
Net profit	9.8	10.9	8.7	11.4	11.3	11.7	11.1	12.6	29.8	35.0	48.2	41.0	46.5	50.3	52.9
Margins	Q1(24)	Q2(24)	Q3(24) Q	Q4(24e) Q	QI(25e) (Q2(25e) (Q3(25e) Q	Q4(25e)	2021	2022	2023	2024e	2025e	2026e	2027e
EBITDA margin	8.9%	9.7%	9.9%	9.1%	9.4%	9.4%	9.5%	9.5%	7.9%	7.4%	8.9%	9.4%	9.5%	9.8%	9.8%
Adj. EBIT margin	6.4%	7.1%	7.2%	7.1%	7.1%	7.1%	7.2%	7.2%	6.0%	5.4%	6.8%	6.9%	7.2%	7.4%	7.4%
EBIT margin	6.4%	7.1%	7.0%	7.1%	7.1%	7.1%	7.2%	7.2%	5.7%	5.4%	6.8%	6.9%	7.2%	7.4%	7.4%
PTP margin	6.5%	7.2%	6.9%	7.0%	7.0%	7.0%	7.1%	7.1%	5.4%	4.9%	6.8%	6.9%	7.1%	7.2%	7.2%
Growth	QI(24)	Q2(24)	Q3(24) Q	Q4(24e) Q	QI(25e) (Q2(25e) (Q3(25e) (Q4(25e)	2021	2022	2023	2024e	2025e	2026e	2027e
Sales growth	-11%	-20%	-19%	-5%	4%	9 %	15%	8%	17%	21%	7%	-14%	9 %	6%	5%
- o/w organic	-10%	-19%	-19%	-9%	-1%	3%	8%	7%	16%	19%	9%	-14%	4%	6%	5%
- o/w structural	0%	0%	0%	4%	5%	5%	5%	0%	0%	0%	0%	1%	4%	0%	0%
- o/w FX	-1%	0%	0%	-1%	0%	1%	1%	1%	0%	3%	-3%	0%	1%	0%	0%
Adj. EBIT growth	-15%	-21%	-18%	11%	16%	9 %	16%	10%	3%	13%	35%	-12%	13%	8%	5%
PTP growth	-11%	-24%	-18%	4%	12%	7%	19%	10%	-10%	11%	48%	-13%	12%	8%	5%

Source: Carnegie Research for forecasts, company data for historical numbers



Carnegie's Sustainability Scorecard

Carnegie total ESG peer rating: 53%

Taxonomy eligible:Yes

Sustainability as a business driver

While perhaps not apparent at first sight, we see several aspects of Scanfil's business model through which sustainability-related trends could serve as a business driver. Firstly, Scanfil has a long history of logistics management, by which the company assists customers to improve the coordination of material flows between sites, find transportation arrangements, and select manufacturing locations optimally sited between customers and suppliers. By minimising the distance required for transportation between supply chain points, Scanfil works to reduce the environmental footprint made by its customers - while also delivering on serviceability and rapid response. The company is also an expert in material handling and product design. By working with the client from early on during the development phase, Scanfil can assist in optimising material management, thus reducing potential waste.

Potential and incidents

40%

60%

80%

100%

20%

Ę

Soc

ğ

0%

Sust. driven growth	Fair
Past incidents	Insignifica

ESG rating - share of best peer score

Exposure to negative impact industries									
Fossil fuels	0%								
Weapons	4%								
Tobacco	0%								
Pornography	0%								
Alcohol	0%								
Gambling	0%								

Source tables and graph above: Carnegie Research

ESG Key Facts


Science-based CO2 reduction targets	na
Science-based CO2 neutrality target yr	na
Non-renewable energy cons. (%)	na
% women (board/senior exec/total)	33/20/45
Employee turnover rate (%)	na
Absenteeism rate (%)	4.2%
Accident frequency (per mill. hours)	na
Board meetings (number/attendance)	17/100%
Sustainability committee	No
Sust. performance in incentive prog.	No
Existence of a whistleblowing system	Yes
Taxonomy eligible revenue	12%

Sustainability targets and achievements

As a member of the UN Global Compact initiative, Scanfil has committed to the principles of human rights, the eradication of corruption, high labour standards, and a sustainable environment. The company has chosen to specify a number of action items within each area of its sustainability work. EcoVadis, a sustainability rating platform, gives Scanfil a silver rating based on its sustainability management system. According to the EcoVadis definitions, this means that the company scores in the 85th percentile among the companies ranked. For 2030, the company aims for a platinum ranking, which would be equivalent to scoring in the 99th percentile. The board of directors and the executive team are responsible for sustainability management at Scanfil.

Sustainability related risks and past incidents

While we have not identified any major sustainability-related incidents in Scanfil's past, we acknowledge that there are some sustainability risks in the company's business model. First and foremost, there is an inherent risk in Scanfil's operations that employees could suffer from health and safety issues stemming from daily operations at the company - for example from operating one of the many machines the company has installed at its sites. To counter instances like this, Scanfil has a Safety Council, which monitors safety, decides on corrective actions and shares best practices.





Financial statements

Profit & loss (EURm)	2017	2018	2019	2020	2021	2022	2023	2024e	2025e	2026e
Sales	530	563	579	595	696	844	902	777	844	895
COGS	-368	-383	-390	-410	-491	-610	-632	-559	-608	-642
Gross profit	162	180	190	185	204	233	270	217	236	253
Other income & costs	-122	-133	-137	-125	-149	-171	-190	-145	-156	-166
Share in ass. operations and JV	0	0	0	0	0	0	0	0	0	0
	40 -7	47 -8	53	60 -9	55 -9	63 -	80	73 -12	80 -12	87
Depreciation PPE	-/	-0 0	-8 -4	-9	-9	-11	-12 -5	-12	-12 -4	-13 -4
Depreciation lease assets Amortisation development costs	0	0	-4		-4	-4	-3	-4	-4	-4
Amortisation other intangibles	-2	-2	-2	-3	-3	-3	-3	-3	-3	-4
Impairments / writedowns	ō	ō	ō	õ	õ	õ	õ	Ő	õ	0
EBITA	31	38	39	44	40	45	61	54	61	66
Amortization acquisition related	0	0	-4	0	0	0	0	0	0	0
Impairment acquisition related	0	0	0	0	0	0	0	0	0	0
EBIT	31	38	35	44	40	45	61	54	61	66
Share in ass. operations and JV	0	0	0	0	0	0	0	0	0	0
Net financial items	1	-2	-1	-3	-2	-4	0	0	-1	-1
of which interest income/expenses	0	0	0	0	0	0	0	0	0 0	0
of which interest on lease liabilities	0	0	0	0	0	0	0	0 0	0	0 0
of which other items Pre-tax profit	33	36	34	42	38	42	62	53	60	64
Taxes	-7	-7	-6	-5	-8	-7	-13	-13	-13	-14
Post-tax minorities interest	, 0	Ó	õ	Ő	õ	, 0	0	0	0	0
Discontinued operations	0	0	0	0	0	0	0	0	Ō	Ō
Net profit	26	29	28	37	30	35	48	41	47	50
Adjusted EBITDA	40	47	57	55	56	63	80	73	80	87
Adjusted EBITA	31	38	43	39	40	45	61	54	61	66
Adjusted EBIT	31	38	39	39	40	45	61	54	61	66
Adjusted net profit	26	29	36	32	30	35	48	41	47	50
Sales growth Y/Y	4.3%	6.3%	2.9%	2.7%	16.9%	21.3%	6.9%	-13.9%	8.7%	6.0%
EBITDA growth Y/Y	120.3%	18.0%	12.1%	14.0%	-8.9%	14.0%	27.9%	-9.0%	9.8%	9.0%
EBITA growth Y/Y	332.3%	20.8%	3.1%	13.9%	-10.8%	14.6%	35.1%	-12.7%	13.3%	8.5%
EBIT growth Y/Y	332.3%	20.8%	-6.4%	25.5%	-10.8%	14.6%	35.1%	-12.7%	13.3%	8.5%
EBITDA margin	7.6%	8.4%	9.1%	10.1%	7.9%	7.4%	8.9%	9.4%	9.5%	9.8%
EBITA margin	5.9%	6.7%	6.7%	7.5%	5.7%	5.4%	6.8%	6.9%	7.2%	7.4%
EBIT margin	5.9%	6.7%	6.1%	7.5%	5.7%	5.4%	6.8%	6.9%	7.2%	7.4%
Tax rate	-20.8%	-19.8%	-17.5%	-11.7%	-21.0%	-16.0%	-21.7%	-23.4%	-22.0%	-22.0%
Cash flow (EURm)	2017	2018	2019	2020	2021	2022	2023	2024e	2025e	2026e
EBITDA	40	47	53	60	55	63	80	73	80	87
Paid taxes	-8	-7	-8	-7	-11	-4	-9	-16	-13	-14
Change in NWC	-6	-10	-8 I	-8	-53	-43 5	-3 -1	42	-5	0
Non cash adjustments	5 0	2 0	0	10 0	4 0	5 0	-1	3 0	15 0	17 0
Discontinued operations Total operating activities	21	29	36	35	-13	10	69	95	47	56
Capex tangible assets Capitalised development costs	-11 0	-9 0	-10 0	-5 0	-12 0	-17 0	-19 0	-16 0	-19 0	-21 0
Capex - other intangible assets	0	0	-7	0	-1	0	-2	-1	-1	-1
Acquisitions/divestments	ő	ŏ	-8	13	0	ŏ	-2	-23	0	-11
Other non-cash adjustments	-1	-1	7	-4	Ī	-2	-1	0	0	0
Total investing activities	-11	-10	-18	4	-13	-19	-22	-39	-20	-32
Net financial items	1	-2	-1	-3	-2	-4	0	0	-1	-1
Lease payments	0	0	0	-4	-4	-4	-4	-4	-4	-4
Dividend paid and received	-6	-7	-8	-10	-11	-12	-14	-15	-15	-17
Share issues & buybacks	0	0	0	I	0	0	0	0	0	0
Change in bank debt	-4	-14	-8	-20	38	20	-30	-9	0	0
Other cash flow items	0	0	0	0	1	0	1	0	0	0
Total financing activities	-11	-22	-18	-34	23	2	-50	-29	-20	-23
Operating cash flow	21	29	36	35	-13	10	69	95	47	56
Free cash flow	11	19	26	26	-25	-8	47	79	27	35
Net cash flow Change in pot IB debt	2 3	-1 	 7	6 28	- I -38	-4 -25	ا 35	28 39	7 9	3 5
Change in net IB debt										
Capex / Sales	2.0%	1.6%	1.7%	0.8%	1.8%	2.0%	2.1%	2.0%	2.3%	2.3%
NWC / Sales	17.2%	17.6%	19.2%	19.8%	20.7%	22.8%	23.8%	25.2%	21.0%	20.0%



Financial statements, cont.

Balance sheet (EURm)	2017	2018	2019	2020	2021	2022	2023	2024e	2025e	2026e
Acquired intangible assets	10	10	8	8	8	8	8	26	26	26
Other fixed intangible assets	15	12	17	14	13	11	10	10	8	5
Capitalised development	0	0	0	0	0	0	0	0	0	0
Tangible assets	48	49	72	65	72	80	85	103	113	123
Lease assets	0	0	21	18	22	24	23	21	24	27
Other IB assets (I)	0	0	0	0	0	0	0	0	0	0
Other non-IB assets	_4	4	6	7	9	8	8	8	8	8
Fixed assets	77	76	103	95	102	107	112	147	154	161
Inventories (2)	101	99	102	103	193	229	209	169	178	181
Receivables (2)	106	108	112	113	149	165	174	151	160	170
Prepaid exp. & other NWC items (2)	I	0	I	I	I	2		2	2	2
IB current assets (1)	0	0	0	0	0	0	0	0	0	0
Other current assets	1 21	2 19	2 20	2 26	3 25	2 21	2 21	5 50	20 57	46 60
Cash & cash equivalents (1) Current assets	230	228	20	26	372	419	406	377	417	458
Total assets	307	304	340	339	474	526	518	524	571	620
Shareholders' equity	125	145	167	183	207	227	266	292	323	357
Minorities	0	0	0	0	0	0	0	0	0	0
Other equity	0	0	0	0	0	0	0	0	0	0
Total equity	125	145	167	183	207	227	266	292	323	357
Deferred tax	5	6	7	6	5	5	6	7	7	7
LT IB debt (I)	27	17	25	18	42	36	0	30	30	30
Other IB provisions (1)	0	0	0	0	0	0	0	0	0	0
Lease libilities	0	0	19	16	20	20	19	17	19	21
Other non-IB liabilities	0	0	0	1			1	12	12	12
LT liabilities	33 34	23	51	40	68	62	25	65	67	70
ST IB debt (I)	113	31 104	23 96	10 100	23 172	50 184	54 167	17 148	17 161	17 174
Payables (2)	0	0	96 0	0	0	184	0	0	0	0
Accrued exp. & other NWC items (2) Other ST non-IB liabilities	2	2	3	6	3	4	5	2	2	2
Liabilities - assets held for sale	0	0	0	0	0	0	0	0	0	0
Current liabilities	149	136	122	116	198	237	227	166	180	193
Total equity and liabilities	307	304	340	339	474	526	518	524	571	620
• •										
Net IB debt (=1)	41	28	46	18	60	86	52	14	9	9
Net working capital (NWC) (=2)	95	104	118	117	171	213	217	174	179	179
Capital employed (CE)	191	198	237	229	295	334	342	369	403	438
Capital invested (CI)	166	173	213	201	267	312	318	306	333	366
Equity / Total assets	41%	48%	49%	54%	44%	43%	51%	56%	57%	58%
Net IB debt / EBITDA	1.0	0.6	0.9	0.3	1.1	1.4	0.6	0.2	0.1	0.1
Per share data (EUR)	2017	2018	2019	2020	2021	2022	2023	2024e	2025e	2026e
Adj. no. of shares in issue YE (m)	63.76	63.95	64.30	64.39	64.70	64.83	64.86	65.19	65.19	65.19
Diluted no. of Shares YE (m)	64.47	64.48	65.13	65.19	65.33	65.74	64.86	65.19	65.19	65.19
EPS	0.40	0.45	0.43	0.57	0.46	0.53	0.74	0.63	0.71	0.77
EPS adj.	0.40	0.45	0.49	0.48	0.49	0.53	0.74	0.63	0.71	0.77
CEPS	0.54	0.60	0.71	0.75	0.63	0.74	0.97	0.87	0.95	1.03
DPS	0.11	0.13	0.15	0.17	0.19	0.21	0.23	0.23	0.24	0.26
BVPS	1.96	2.26	2.59	2.84	3.21	3.50	4.10	4.48	4.96	5.47
Performance measures	2017	2018	2019	2020	2021	2022	2023	2024e	2025e	2026e
ROE	22.2%	21.4%	18.0%	21.1%	15.2%	16.1%	19.6%	14.7%	15.1%	14.8%
Adj. ROCE pre-tax	16.4%	19.0%	16.6%	17.0%	13.6%	13.6%	17.9%	14.6%	15.1%	15.0%
Adj. ROIC after-tax	14.8%	17.7%	15.7%	17.0%	12.1%	12.4%	15.1%	13.5%	14.3%	14.1%
Valuation	2017	2018	2019	2020	2021	2022	2023	2024e	2025e	2026e
FCF yield	2.0%	3.6%	4.8%	4.8%	-4.6%	-1.5%	8.7%	14.6%	4.9%	6.5%
Dividend yield YE	na	na	3.1%	2.6%	2.5%	3.1%	2.9%	2.8%	2.9%	3.1%
Dividend payout ratio	27.4%	29.0%	34.6%	30.2%	41.7%	38.8%	31.0%	37.0%	33.3%	33.3%
Dividend + buy backs yield YE	na	na	3.0%	2.6%	2.5%	3.1%	3.0%	2.8%	3.1%	3.3%
			0.42	0.74	0.70	0.41	0.42	0.71	0.45	0.41
EV/Sales YE	na	na	0.63	0.74	0.79	0.61	0.62	0.71	0.65	0.61
EV/EBITDA YE	na	na	6.9	7.3	10.0	8.3	7.0	7.6	6.9	6.3
EV/EBITA YE	na	na	9.4	10.0	13.8	11.4	9.1	10.3	9.1	8.4
EV/EBITA adj. YE	na	na	8.5	11.4	13.6	11.5	9.2	10.2	9.1	8.4
EV/EBIT YE	na	na	10.3	10.0	13.8	11.4	9.1	10.3	9.1	8.4
P/E YE	na	na	11.3	11.5	16.4	12.3	10.5	13.1	11.6	10.8
P/E adj. YE	na	na	10.0	13.5	15.2	12.3	10.5	13.1	11.6	10.8
P/BV YE	na	na	1.89	2.30	2.33	1.88	1.91	1.84	1.67	1.52
Share price YE (EUR)			4.89	6.52	7.46	6.58	7.83	8.25	8.30	



Disclosures and disclaimers

Carnegie Investment Bank AB

Carnegie Investment Bank AB (publ.) is a leading investment bank with a Nordic focus. The Carnegie group of companies, together "Carnegie", generates added value for institutions, companies and private clients in the areas of trade in securities, investment banking and private banking. Carnegie has approximately 600 employees, located in offices in six countries

Valuation, methodology, and assumptions

Commissioned research reports include the analyst's assessment of a fair value range over the coming six to 12 months based on various fundamental valuation methods. A commonly used method is DCF valuation, where future cash flows are discounted to today. Analysts may also use different valuation multiples, e.g. P/E ratio and EV/EBIT multiples, relative to industry peers to obtain a target price. For companies where it is appropriate, a fair value range can also be based on the analyst's assessment of a fair ratio relative to then asset value of the company. Fair value ranges represent the assessment of the analyst(s) at the time of writing

Frequency of update

Carnegie's research analysis consists of case-based analyses, which implies that the frequency of the analytical report may vary over time. Unless otherwise expressly stated in the report, the analysis is updated when considered necessary by the research department, for example in the event of significant changes in market conditions or events related to the issuer/the financial instrument.

Analyst certification

The research analyst or analysts responsible for the content of this commissioned research report certify that, notwithstanding the existence of any potential conflicts of interests referred to herein, the views expressed in this commissioned research report accurately reflect the research analyst's personal views about the companies and securities covered. It is further certified that the research analyst has not been, nor is or will be, receiving direct or indirect compensation related to the specific ratings or views contained in this commissioned research report.

Potential conflicts of interest

Carnegie, or its subsidiaries, may from time to time perform investment banking or other services for, or solicit investment banking or other business from, any company mentioned in this report. Any such publicly announced business activity, during the past 12 months, will be referred to in this commissioned research report. A set of rules handling conflicts of interest is implemented in the Carnegie Group. Investment Banking and other business departments in Carnegie are surrounded by information barriers to restrict the flows of sensitive information. Persons outside such barriers may gain access to sensitive information only after having observed applicable procedures. The remuneration of persons involved in preparing this commissioned research report is not tied to investment banking transactions performed by Carnegie or a legal person within the same group.

Confidential and non-public information regarding Carnegie and its clients, business activities and other circumstances that could affect the market value of a security ("sensitive information") is kept strictly confidential and may never be used in an undue manner.

Internal guidelines are implemented in order to ensure the integrity and independence of research analysts. In accordance with the guidelines the research department is separated from the Investment Banking department and there are no reporting lines between the research department and Investment Banking. The guidelines also include rules regarding, but not limited to, the following issues; contacts with covered companies, prohibition against offering favourable recommendations, personal involvement in covered companies, participation in investment banking activities, supervision and review of research reports, analyst reporting lines and analyst remuneration.

Other material conflicts of interest

This report was commissioned and sponsored by the issuer (issuer-paid research).

Distribution restrictions

This commissioned research report is intended only for distribution to professional investors. Such investors are expected to make their own investment decisions without undue reliance on this commissioned research report. This commissioned research report does not have regard to the specific investment objectives, financial situation or particular needs of any specific person who may receive it. Investors should seek financial advice regarding the appropriateness of investing in any securities discussed in this commissioned research report and should understand that statements regarding future prospects may not be realized. Past performance is not necessarily a guide to future performance. Carnegie and its subsidiaries accept no liability whatsoever for any direct or consequential loss, including, without limitation, any loss of profits arising from the use of this commissioned research report or its contents. This commissioned research report may not be reproduced, distributed or published by any recipient for any purpose. The document may not be distributed to persons that are citizens of or domiciled in any country in which such distribution is prohibited according to applicable laws or other regulations.

This commissioned research report is distributed in Sweden by Carnegie Investment Bank AB. Carnegie Investment Bank AB is a bank incorporated in Sweden with limited liability which is authorised and regulated by the Swedish Financial Supervisory Authority (Finansinspektionen). In Finland this commissioned research report is issued by Carnegie Investment Bank AB, Finland Branch. The Finland branch is authorised by the Swedish Financial Supervisory Authority and subject to limited regulation by the Finnish Financial Supervisory Authority (Finansiti/avonta). In Norway this commissioned research report is issued by Carnegie AS, a wholly-owned subsidiary of Carnegie Investment Bank AB. Carnegie AS is regulated by the Financial Supervisory Authority of Norway (Finanstilsynet). In Denmark this commissioned research report is issued by Carnegie Investment Bank AB, Denmark Branch. The Denmark branch is authorised by the Swedish Financial Supervisory Authority and subject to limited regulation by the Danish Financial Supervisory Authority (Finanstilsynet).

subject to limited regulation by the Danish Financial Supervisory Authority (Finanstilsynet). This commissioned research report is distributed in the US by Carnegie, Inc., a US-registered broker-dealer and a member of FINRA and SIPC. Carnegie's research analysts located outside of the US are employed by non-US affiliates of Carnegie Inc. ("non-US affiliates") that are not subject to FINRA regulations. Generally, Carnegie research analysts are not registered with or qualified as research analysts with FINRA, and therefore are not subject to FINRA rule 2241 restrictions intended to prevent conflicts of interest by, among other things, prohibiting certain compensation practices, restricting trading by analysts and restricting communications with the companies that are the subject of the research report. Research reports distributed in the U.S. are intended solely for major US institutional investors and US institutional investors as defined under Rule ISa-6 of the Securities Exchange Act of 1934. This commissioned research report is provided for informational purposes only and under no circumstances is it to be used or considered as an offer to sell, or a solicitation of any offer to buy any securities. Reports regarding equity products are prepared by non-US affiliates of and distributed in the United States by Carnegie Inc. under Rule ISa-6(a)(3). When distributed by Carnegie Inc, Carnegie Inc, takes subject to, the current information report any US person who wishes to effect transactions based on this commissioned research report. Any US person who wishes to effect transactions based on this commissioned research reporting and audit standards of the US should be aware that investing in non-US securities entails certain risks. The securities of non-US issuers may not be registered with, or be subject to, the current information reporting and audit standards of the US Securities and Exchange Commission. This commissioned research report has been issued in the UK by Carnegie UK which is the UK Branch of Carnegie

Research Disclaimer

This commissioned research report is provided solely for information. It does not constitute or form part of, and shall under no circumstances be considered as an offer to sell or a solicitation of an offer to purchase or sell any relevant financial instrument.

This commissioned research report has been requested and paid for by the issuer and should therefore be considered a marketing communication (i.e. not investment research). Payment for the report has been agreed in advance on a non-recourse basis. As commissioned research, this material can be considered an acceptable minor non-monetary benefit under MiFID II. It has not been prepared in accordance with the legal requirements designed to promote the independence of investment research. However, it is still subject to a prohibition on dealing ahead of the dissemination of the report.

Carnegie Investment Bank AB is responsible for the preparation of this commissioned research report in Sweden, Finland, Denmark, and the UK. Carnegie AS is responsible for the preparation of this commissioned research report in Norway. Carnegie Inc. is responsible for this research report in the US.

The information in this commissioned research report was obtained from various sources. While all reasonable care has been taken to ensure that the information is true and not misleading. Carnegie gives no representation or warranty, express or implied, about its accuracy or completeness. Carnegie, its subsidiaries and any of their officers or directors may have a position, or otherwise be interested in, transactions in securities that are directly or indirectly the subject of this commissioned research report. Any significant financial interests held by the analyst, Carnegie or a legal person in the same group in relation to the issuer will be referred to in the company-specific disclosures.

Company specific disclosures

The following disclosures relate to relationships between Carnegie Investment Bank AB (with its subsidiaries, "Carnegie") and the issuer or an affiliate.

Parts of this commissioned research report may have been submitted to the issuer prior to its publication.

Copyright © 2025 Carnegie



Commissioned Research sponsored by Scanfil

13 January 2025

Carnegie Investment Bank AB

Regeringsgatan 56 SE-103 38 Stockholm Tel +46 8 5886 88 00 Fax +46 8 5886 88 95 www.carnegie.se A member of the Stockholm Stock Exchange

Carnegie AS

Fjordalleen 16, 5th Floor PO Box 684, Sentrum NO-0106 Oslo Tel +47 22 00 93 00 Fax +47 22 00 94 00 www.carnegie.no A member of the Oslo Stock Exchange Carnegie Investment Bank, Denmark Branch Overgaden neden Vandet 9B PO Box 1935 DK-1414 Copenhagen K Tel +45 32 88 02 00 Fax +45 32 96 10 22 www.carnegie.dk A member of the Copenhagen Stock Exchange

Carnegie, Inc.

20 West 55th St. , New York N.Y. 10019 Tel +1 212 262 5800 Fax +1 212 265 3946 www.carnegiegroup.com Member FINRA / SIPC Carnegie Investment Bank AB, Finland Branch Eteläesplanadi 2 PO Box 36 FI-00131 Helsinki Tel +358 9 618 71 230 Fax +358 9 618 71 720 www.carnegie.fi A member of the Helsinki Stock Exchange

Carnegie Investment Bank AB, UK Branch

Finwell House, 26 Finsbury Square London EC2A IDS Tel +44 20 7216 4000 Fax +44 20 7417 9426 www.carnegie.co.uk Regulated by the FCA in the conduct of Designated Investment Business in the UK